Dr. Giralt on Allogeneic HCT in Multiple Myeloma

Video

Sergio A. Giralt, MD, discusses the role of allogeneic hematopoietic cell therapy in patients with multiple myeloma.

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, the Melvin Berlin Family Chair in Multiple Myeloma, and chief attending of adult bone marrow transplant service at Memorial Sloan Kettering Cancer Center, discusses the role of allogeneic hematopoietic cell therapy (HCT) in patients with multiple myeloma.

Giralt says this is a valid option for patients and should not be dismissed. This option has been available to patients for over 2 decades, though experts are aware that the results aren’t exactly what they hope. A number of clinical trials are exploring allogeneic HCT to improve the outcomes for these patients.

In particular, allogenic HCT provides a chance for long-term disease control in younger patients who have experienced multiple relapses.

<<< 2019 Transplantation and Cellular Therapy Meetings

Related Videos
Joseph Mikhael, MD
Ariel F. Grajales-Cruz, MD, Moffitt Cancer Center
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Joshua Richter, MD
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine